drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Humanized anti-HER2 IgG1 monoclonal antibody (trastuzumab-like) that binds the HER2 extracellular domain, inhibits HER2 signaling, and mediates Fc-dependent ADCC.
nci_thesaurus_concept_id
C179282
nci_thesaurus_definition
An Fc-engineered monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential immunomodulating and antineoplastic activities. Upon administration, inetetamab targets and specifically binds to HER2 on tumor cells, thereby blocking HER2-mediated signaling. This may inhibit proliferation of HER2-expressing tumor cells. In addition, the Fab region of inetetamab may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 (ErbB2) IgG1 monoclonal antibody that binds the HER2 extracellular domain, blocks HER2-mediated signaling/dimerization, inhibits proliferation of HER2-overexpressing tumor cells, and triggers Fc-dependent ADCC.
drug_name
Inetetamab
nct_id_drug_ref
NCT06578299